<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714959</url>
  </required_header>
  <id_info>
    <org_study_id>1510112713</org_study_id>
    <nct_id>NCT02714959</nct_id>
  </id_info>
  <brief_title>IL-2 in Refractory Autoimmune Encephalitis</brief_title>
  <official_title>Effect of IL-2 in Refractory Autoimmune Encephalitis Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether low-dose IL-2 is effective in refractory
      autoimmune encephalitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autoimmune encephalitis is a recently recognized etiology of encephalitis which is mediated
      by various autoantibodies targeting neural cells or synapses. The responses to immunotherapy
      is generally good, considerable proportion of patients with autoimmune encephalitis have
      unfavorable clinical outcomes. Recently, depletion of regulatory T cell (Treg cell) is
      reported in variable autoimmune diseases and multiple studies have shown that low-dose
      interleukin-2(IL-2) specifically activates Treg cells to control autoimmunity and
      inflammation.

      Protocol: This study is a single arm open-label study assessing clinical responses to the
      administration of low-dose IL-2 in autoimmune encephalitis patients who are refractory to
      first- and second-line immunotherapy.

      Objective: To assess the efficacy of low-dose IL-2 in autoimmune encephalitis, resistant to
      first- and second- line immunotherapy.

      Methods: This is a single arm open-label study. Each patients will receive four cycles of
      subcutaneous Proleukin (Interleukin-2, IL-2) (Week-1; 1.5 million IU (MIU)/d from Day-1 to
      Day-5, Week-3, -6, -9; 3MIU/d from Day-1 to Day-5) in the hospital. The patients will be
      followed up for 3 months (Week-21).

      Primary outcome - clinical efficacy by modified Rankin Scale Secondary outcome - Immunologic
      follow-up of Treg cells before, during, and after IL-2 therapy, quality of life, cognitive
      function, side effect of low-dose IL-2
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of modified Rankin scale</measure>
    <time_frame>Week 0,12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change of percentage of regulatory T (Treg) cells</measure>
    <time_frame>Week 1, 3, 5, 9, 12, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Week 1, 3, 5, 9, 12, 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Week 21</time_frame>
    <description>Quality of Life in Epilepsy Inventory (QOLIE)-31</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Week 21</time_frame>
    <description>Beck Depression Inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>Week 21</time_frame>
    <description>Mini-mental state examination (MMSE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Encephalitis</condition>
  <arm_group>
    <arm_group_label>Proleukin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Proleukin (subcutaneous injection) 1.5 MIU/day from day 1 to 5 at W1 3 MIU/day from day 1 to day 5 at W3, W6, and W9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proleukin</intervention_name>
    <arm_group_label>Proleukin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Clinical diagnosis of autoimmune encephalitis

          -  Positive for autoantibody (serum and or CSF) : NMDAR, anti-leucine-rich glioma
             inactivated-1(LGI-1), contactin-associated protein-like 2 (CASPR2),
             α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) 1, AMPA2,
             GABAB-R, anti-Hu, -Yo, -Ri, -Ma2, -CV2/collapsing response mediator protein 5 (CRMP5),
             -amphiphysin, or glutamic acid decarboxylase (GAD)

          -  Refractory to first-line (high-dose steroid or intravenous immunoglobulin) and second
             line (rituximab or cyclophosphamide) immunotherapy

          -  Written informed consent form.

        Exclusion Criteria:

          -  low hemoglobin &lt;8.0 g/dL, absolute neutrophil count&lt;1600/mm3, lymphocytes &lt;600/mm3,
             platelets &lt;140,000/mm3

          -  heart failure (≥ grade III NYHA), hepatic insufficiency (aspartate amino transferase
             &gt;200 IU/L, amino alanine transferase, &gt;200 IU/L), or lung failure

          -  Positive for HIV serology, active hepatitis B

          -  Significant abnormality in chest X-ray other than these linked to the diseases under
             investigation

          -  Infection

          -  Other progressive neurological degenerative disease.

          -  Poor venous access not allowing repeated blood tests

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chu Kon, MD, PhD</last_name>
    <email>stemcell.snu@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015 May;15(5):283-94. doi: 10.1038/nri3823. Epub 2015 Apr 17. Review.</citation>
    <PMID>25882245</PMID>
  </reference>
  <reference>
    <citation>Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011 Dec 1;365(22):2067-77. doi: 10.1056/NEJMoa1105143. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.</citation>
    <PMID>22129253</PMID>
  </reference>
  <reference>
    <citation>Hartemann A, Bensimon G, Payan CA, Jacqueminet S, Bourron O, Nicolas N, Fonfrede M, Rosenzwajg M, Bernard C, Klatzmann D. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305. doi: 10.1016/S2213-8587(13)70113-X. Epub 2013 Oct 8.</citation>
    <PMID>24622415</PMID>
  </reference>
  <reference>
    <citation>Rosenzwajg M, Churlaud G, Mallone R, Six A, Dérian N, Chaara W, Lorenzon R, Long SA, Buckner JH, Afonso G, Pham HP, Hartemann A, Yu A, Pugliese A, Malek TR, Klatzmann D. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients. J Autoimmun. 2015 Apr;58:48-58. doi: 10.1016/j.jaut.2015.01.001. Epub 2015 Jan 26.</citation>
    <PMID>25634360</PMID>
  </reference>
  <reference>
    <citation>Castela E, Le Duff F, Butori C, Ticchioni M, Hofman P, Bahadoran P, Lacour JP, Passeron T. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol. 2014 Jul;150(7):748-51. doi: 10.1001/jamadermatol.2014.504.</citation>
    <PMID>24872229</PMID>
  </reference>
  <reference>
    <citation>Humrich JY, von Spee-Mayer C, Siegert E, Alexander T, Hiepe F, Radbruch A, Burmester GR, Riemekasten G. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE. Ann Rheum Dis. 2015 Apr;74(4):791-2. doi: 10.1136/annrheumdis-2014-206506. Epub 2015 Jan 21.</citation>
    <PMID>25609413</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2016</study_first_submitted>
  <study_first_submitted_qc>March 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2016</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kon Chu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

